Home CNS ICER Final Report on Spravato Puts in the ‘Low Value for Money’...

ICER Final Report on Spravato Puts in the ‘Low Value for Money’ Category for the Depression Drug

186
0
The phychiatrist prescribing man with medical depression

Janssen (J&J) Esketamine recently was approved as an antidepressant by the FDA. Called Spravato, the original cat tranquilizer was used for off-label treatment of severe depression. ICER determined that a fair and rational price for the anti-depression drug is between $`7700 and $25,200 per year. This represents a 25-52% discount on J&J’s annual list price of $32,400.

The ICER analysis would put Spravato in the “low value for money” category as the treatment’s incremental cost-effectiveness ratio exceeds $175,000 per quality-adjusted life year (QALY) gained.

LEAVE A REPLY

Please enter your comment!
Please enter your name here

This site uses Akismet to reduce spam. Learn how your comment data is processed.